CareersInvestor RelationsPress Room
  1. Home
  2. Press Room
  3. UK & Ireland Press Releases
  4. Siemens Healthineers announces two new combination tests for both SARS-CoV-2 and other seasonal respiratory pathogens

Siemens Healthineers announces two new combination tests for both SARS-CoV-2 and other seasonal respiratory pathogens

  • The FTD SARS-CoV-2/FluA/FluB/HRSV1 PCR test enables comprehensive, semi-automated, mid- to high-throughput testing for common and potentially serious seasonal respiratory pathogens. 
  • For point-of-care applications, the CLINITEST Rapid COVID-19 + Influenza Antigen Test delivers reliable results in 15 minutes to detect both SARS-CoV-2 and influenza to enable effective and timely management of these viral illnesses.
  • Both tests enable effective management of seasonal respiratory testing during, and beyond, the current COVID-19 pandemic.

United Kingdom

|2022-10-03
CLINITEST Rapid COVID-19 + Influenza Antigen Test from Siemens Healthineers.

CLINITEST Rapid COVID-19 + Influenza Antigen Test from Siemens Healthineers.

Siemens Healthineers has announced the release of its new CE-marked FTD SARS-CoV-2/FluA/FluB/HRSV Assay, a PCR test, and the CLINITEST Rapid COVID-19 + Influenza Antigen Test.1,2

FTD SARS-CoV-2/FluA/FluB/HRSV combination PCR test 

Validated on the company’s VERSANT kPCR Molecular System, the kit combines Siemens Healthineers FTD SARS-CoV-23 and FTD Flu/HRSV Assays.1 The new FTD SARS-CoV-2/FluA/FluB/HRSV Assay enables comprehensive and semi-automated molecular testing for seasonal respiratory pathogens. The combination PCR test detects and differentiates between clinically relevant viruses: SARS-CoV-2, Influenza A, Influenza B, and HRSV A/B. Preserving sensitivity via the separate detection of SARS-CoV-2 targets allows the company’s highly effective, proven FTD SARS-CoV-2 Assay to perform without any compromise to sensitivity, maintaining key features of the top-performing assay.

CLINITEST Rapid COVID-19 + Influenza A/B Antigen Test 

This convenient 3-in-1 test, administered by a healthcare professional in virtually any medical setting, provides reliable results in 15 minutes. With no instrumentation or equipment required, a single nasopharyngeal swab sample can differentiate between SARS-CoV-2, Influenza A, and Influenza B infections. This test provides high sensitivity and specificity (98.32%/99.60% for SARS-CoV-2, 88.57%/97.78% for Flu A, and 87.10%/97.87% for Flu B). Results can facilitate prompt self-isolation of infected patients, if deemed necessary, to prevent the spread of SARS-CoV-2 and influenza.

“As we approach the high season for cold and flu viruses in the UK, with the additional presence of COVID-19, it’s imperative we enable healthcare professionals with the right tools to differentiate between these infections,” states Stewart Hutton, Head of Diagnostics, Siemens Healthineers GB&I. "With A&E and hospital settings under pressure, the CLINITEST Rapid COVID-19 + Influenza A/B Antigen Test from Siemens Healthineers provides results in 15 minutes, prompting timely management of viral infections and helping to reduce the spread of SARS-CoV-2 and seasonal respiratory viruses.”

1 Not available for sale in the U.S. Product availability may vary by country.

2 CLINITEST and all associated marks are trademarks of Siemens Healthcare Diagnostics Inc., or its affiliates.

3 CE-IVD–labelled for diagnostic use in the EU. This test has not been FDA-cleared or approved. This test has been authorised by FDA under an EUA for use by authorised laboratories. This test has been authorised only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens. This test is only authorised for the duration of the declaration that circumstances exist justifying the authorisation of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21. U.S.C. § 360bbb- 3(b)(1), unless the authorisation is terminated or revoked sooner.